|
EPB41L5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69186886722628E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.80711001718237E-12 |
| Normal-vs-Stage2 |
1.4450662888521E-12 |
| Normal-vs-Stage3 |
2.83106871279415E-14 |
| Normal-vs-Stage4 |
2.1538326677728E-14 |
| Stage1-vs-Stage2 |
9.349800E-01 |
| Stage1-vs-Stage3 |
3.289200E-01 |
| Stage1-vs-Stage4 |
1.729220E-01 |
| Stage2-vs-Stage3 |
5.332800E-01 |
| Stage2-vs-Stage4 |
2.581200E-01 |
| Stage3-vs-Stage4 |
5.567400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.71396230541632E-12 |
| Normal-vs-AfricanAmerican |
8.5930999982331E-08 |
| Normal-vs-Asian |
1.77802217393719E-12 |
| Caucasian-vs-AfricanAmerican |
7.950200E-01 |
| Caucasian-vs-Asian |
5.486000E-01 |
| AfricanAmerican-vs-Asian |
5.070200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.85240711658707E-12 |
| Normal-vs-Female |
1.67954539165294E-12 |
| Male-vs-Female |
6.637200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.13018491734829E-12 |
| Normal-vs-Age(41-60Yrs) |
1.67688085639384E-12 |
| Normal-vs-Age(61-80Yrs) |
1.765254609154E-14 |
| Normal-vs-Age(81-100Yrs) |
8.800900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.861200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.784210E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.860200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.505600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.579600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.902200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.377300E-03 |
| Classical-VS-Follicular |
2.791600E-01 |
| Classical-VS-Other |
6.167800E-02 |
| Classical-VS-Normal |
3.18389759002002E-12 |
| Tall-VS-Follicular |
9.056200E-02 |
| Tall-VS-Other |
9.383400E-01 |
| Tall-VS-Normal |
3.99680288865056E-15 |
| Follicular-VS-Other |
4.197400E-01 |
| Follicular-VS-Normal |
1.87594384470913E-12 |
| Other-VS-Normal |
1.72799996533968E-09 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.65101265992007E-12 |
| Normal-vs-N1 |
2.54463117244086E-13 |
| N0-vs-N1 |
5.575000E-01 |
|
|
